Following the daily administration of vaporized plant cannabis, the patient exhibited sustained improvements in speech fluency and also reported benefits to his overall quality of life. The patient did not report any adverse side effects from cannabis over the one-year observational period.
Category: Prohibition Doesn’t Work
Legal marijuana sales have increased to historic levels in recent months, with sales totaling nearly $6 billion in the first quarter of this year.
The new rules raise the amount of THC permissible in a single serving of an adult-use edible product from 5mg of THC to 10mg.
The combined administration of oral THC (dronabinol) and the endogenous compound PEA (palmitoylethanolamide) is associated with symptomatic improvements in patients with treatment-resistant Tourette’s syndrome (TS), according to observational trial data published in the Journal of Neuropsychiatry and Clinical Neurosciences. A team of Yale University researchers assessed the use of THX-110 (a proprietary combination of THC and PEA) over a period … Continue reading Study reveals THC effective in treating Tourettes
House Bill 605 permits physicians to recommend cannabis therapy to patients with opioid use disorder. Some studies have shown that the use of cannabis is associated with greater rates of treatment retention in patients with OUD and that cannabinoids may mitigate opioid-related cravings.
Twenty-five percent of respondents acknowledged either using or having used CBD for symptom control. Nearly half (46 percent) of users reported that it mitigated their pain.
Members of the Israeli Parliament have narrowly defeated legislation that sought to depenalize activities involving the possession and cultivation of cannabis by adults. The proposal sought to eliminate criminal and civil penalties involving the possession of up to 50 grams of cannabis and/or the home-cultivation of personal use quantities of the plant. The legislation failed in the … Continue reading Knesset nearly legalizes cannabis possession
Researchers affiliated with Pure Green Pharmaceuticals assessed the efficacy of sublingual CBD tablets (20mg) versus placebo in a cohort of subjects with painful diabetic peripheral neuropathy (pDPN) pain in their feet.
Following treatment, subjects’ average pain intensity declined from baseline by 20 percent. Nearly half of the subjects who had been using analgesic medications at the start of trial were no longer using them by the study’s end.
DonnyFerguson.com 